6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione hydrochloride

• ChemBase编号: 73241
• 分子式: C20H30ClN5O3
• 平均质量: 423.9369
• 单一同位素质量: 423.20371753
• SMILES: n1(c(=O)n(c(cc1=O)NCCCN1CCN(CC1)c1ccccc1OC)C)C.Cl
• Canonical SMILES: COc1ccccc1N1CCN(CC1)CCCNc1cc(=O)n(c(=O)n1C)C.Cl
• InChI: InChI=1S/C20H29N5O3.ClH/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3;/h4-5,7-8,15,21H,6,9-14H2,1-3H3;1H
• InChIKey: KTMLZVUAXJERAT-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione hydrochloride
• IUPAC传统名: urapidil hydrochloride
• 别名: Urapidil hydrochloride; 6-[[3-[4-(o-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil hydrochloride; Urapidil hydrochloride; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione Hydrochloride

登记号

• CAS号: 64887-14-5
• MDL号: MFCD00078601
• PubChem SID: 24277811; 162038161
• PubChem CID: 167980

理论计算性质

• 质子受体: 6
• 质子供体: 1
• LogD (pH = 5.5): -1.3816706
• LogD (pH = 7.4): 0.39269504
• Log P: 1.1826149
• 摩尔折射率: 119.3696 cm^3
• 极化性: 41.324097 Å^3
• 极化表面积: 68.36 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO; H2O: soluble; Methanol
• 外观: white solid; White to Off-White Solid
• 熔点: 236-241°C

安全信息

• 保存条件: -20°C; Refrigerator
• RTECS编号: YQ9862000
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22
• 安全公开号: 36
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves

药理学性质

• 作用靶点: adrenergic receptor
• 相关基因信息: human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), HTR1A(3350)

产品相关信息

• 成盐信息: hydrochloride

详细说明

Selleck Chemicals - S2025

Research Area: Cancer
Biological Activity:
Urapidil hydrochloride is a hydrochloride salt form of urapidil which is α1-adrenoceptor antagonist and 5-HT1A receptor agonist with pIC50 of 6.13 and 6.4 respectively. Urapidil has an alpha-blocking effect but, unlike other alpha-blockers, also has a central sympatholytic effect mediated via stimulation of serotonin 5HT1A receptors in the central nervous system. [1] Oral urapidil is effective and well tolerated when used as second-line therapy in patients with blood pressure inadequately controlled with other agents. Urapidil has also been demonstrated to ameliorate glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia. Intravenous urapidil is effective in the treatment of hypertensive crises, perioperative hypertension, and pre-eclampsia and may have a potential role in the management of acute stroke. [2]References on Urapidil HCl[1] Am J Cardiol., 1989, 64(7):1D-6D[2] Adv Ther., 2010, 27(7):426-43

Sigma Aldrich - U100

Biochem/physiol Actions
α1-adrenoceptor antagonist; 5-HT1A serotonin receptor partial agonist; anti-hypertensive.

Toronto Research Chemicals - U815400

α1-Adrenergic antagonist; derivative of Uracil (U801000). Antihypertensive.

参考文献

• Buch J.Adv Ther. 2010; 27(7):426-43.
• Eltze, M., et al.: Eur. J. Pharmacol., 59, 1 (1979)
• Barankay, A., et al.: Arzneim.-Forsch., 31, 849 (1979)
• Belz, G.G., et al.: Clin. Pharmacol. Ther., 37, 48 (1979)